Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole vs Voriconazole for First-line Treatment of Invasive Aspergillosis
CTR20150263Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of posaconazole in invasive aspergillosis (IA), invasive mycoses, sponsored by Merck & Co.. Started Jun 2016; status: completed.
02
Drugs
posaconazole
03
Conditions
invasive aspergillosis (IA)invasive mycoses
Beyond the preview
Go deeper on CTR20150263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150263.